Work

Stereotactic ablative radiotherapy for central and ultra-central lung tumors

Year: 2019

Type: article

Abstract: Stereotactic ablative radiotherapy (SABR) has emerged as a standard-of-care treatment for patients with early stage non-small cell lung cancer (NSCLC) who are poor surgical candidates. Current evidence supports the consensus that lung SABR with BED ≥100 Gy leads to high local tumor control, and that the treatment is generally well-tolerated when applied to peripheral lung tumors. However, several studies present conflicting evidence for the treatment of central and ultra-central lung tumors, with some showing superb outcomes and others showing concerning rates of morbidity and mortality. Therefore, treatment of central and especially ultra-central lung tumors with SABR remains controversial. In this review, we aim to present the existing evidence for SABR treatment of central and ultra-central lung tumors and delineate the factors that could lead to significant toxicity.

Source: Therapeutic Radiology and Oncology

DOI: 10.21037/tro.2019.05.01

Authors: Aadel A. Chaudhuri, Kevin Chen, Maximilian Diehn, Billy W. Loo Jr

Institutions: Washington University in St. Louis, Stanford Medicine, Stanford Cancer Institute, Stanford University

Language: English

Topic: Lung Cancer Diagnosis and Treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Funder: National Cancer Institute